RA patients develop resistance to Humira, study finds; Roche, FDA disagree on Avastin hearing;

@FiercePharma: Report: Roche, Novartis poised for personalized pharma. Item | Follow @FiercePharma

> Abbott Laboratories' Humira spurred resistance in more than a quarter of patients taking the rheumatoid arthritis drug in a study, a finding that may weaken demand for the company's top-selling medicine. Report

> Despite weeks of haggling, Roche and the FDA remain unable to agree on the questions to be addressed during a June hearing over Avastin's use in metastatic breast cancer. Story

> In another blow to diet drugs, Canadian researchers are reporting a suggested link between Roche's Xenical and an increase in kidney injuries. News

> Glioblastoma multiforme, a malignant brain tumor, is frustratingly elusive because it can appear in many forms. A team of researchers from the University of Cincinnati hope to shine a light on the brain tumor's multiple personalities by sequencing individual glioblastoma genomes and tracking abnormalities through the bloodstream, the university announced in a release. Story

> Researchers had a gut feeling that gastrointestinal bacteria are harmed by stress, which then weakens the entire immune system, but it took two biomarkers to help them prove it. Article

> An Inspire Pharmaceuticals shareholder filed a lawsuit claiming Merck's $430 million offer for the eye-care company is inadequate. Report

> In many ways, biomarkers are only as effective as the biosensors available to detect and monitor them. FDA and the Defense Advanced Research Projects Agency (DARPA), which funds high-risk technology, are getting together to accelerate development and approval of devices that can continuously monitor biomarkers in people. News

> Actelion would consider a sale if a suitor makes an offer "even close" to what the Swiss biotechnology company considers to be its value, Reuters reported, citing Chairman Robert Cawthorn. Article

> Bristol-Myers Squibb's Mount Vernon, Indiana, operation is contracting out its logistics and distribution activities to Exel, a third-party logistics provider. Item

> Novartis will soon launch a global review of the media portion of its more than $600 million advertising account, several industry executives have indicated to Ad Age. Report

> Bank of America upgraded shares of Biogen from neutral to buy as sales growth for the company's multiple sclerosis drug is tracking higher than expected; the bank set a $89 price target. Story

> Shanghai Pharmaceuticals said China's securities regulator approved its plan to issue up to 763.85 million so-called H shares in an initial public offering in Hong Kong. News

Biotech News

 @FierceBiotech: Exelixis spurs takeover rumors with Goldman ploy. News | Follow @FierceBiotech

 @JohnCFierce: Novartis gets expert panel support for its blockbuster Afinitor as a treatment for pancreatic cancer. Report | Follow @JohnCFierce

> Successful biotechs try to fend off Big Pharma. News 

> Investors pony up $21M for F-star's antibody work. Item 

> Safinamide shows promising Ph3 results against dyskinesia. Story 

> Pfizer, FoldRx drug extends survival. Article 

> Report: Actelion would consider sale at the right price. News

Drug Delivery News

> Report: Monoclonal antibodies set to drive drug-delivery growth. News

> Modified herpes simplex virus delivers anti-pain gene therapy. Story

> Study: Most kids do not use inhalers properly. Article

> Nano-capsules may solve solubility problem of anti-cancer drug. Report

> Taming photosensitive chemicals to deliver drugs. Item

Medical Device News

> Biomet announces Q3 results. News

> Mirador closes $1.5M Series B funding round. Article

> Lanx launches Durango, Concero systems. Item

> Shuren to appear on Capitol Hill to discuss FDA approvals. Report

> ReGen files for Chapter 11 bankruptcy protection. Story

And Finally... Good news for women in their 50s--the health risks related to hormone therapy with estrogen might go away after they stop the treatments. Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.